Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.33 |
| ▸ | FAAH | O00519 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30072242 | 0.84 | TRPA1 (0.33) | TRPA1 | |
| SCHEMBL15275536 | 0.84 | GABRA1 (0.41) | CA1CA2CA12CA9GABRA1 | |
| SCHEMBL333685 | 0.84 | ALDH1A1 (0.30) | ALDH1A1L3MBTL1 | |
| SCHEMBL29492107 | 0.84 | ALDH1A1 (0.30) | ALDH1A1L3MBTL1 | |
| SCHEMBL165778 | 0.78 | ROCK2 (0.35) | GABRA1GABRB2 | |
| SCHEMBL31633546 | 0.78 | — | — | |
| SCHEMBL29353263 | 0.78 | ROCK2 (0.35) | GABRA1GABRB2 | |
| SCHEMBL167078 | 0.77 | GABRA1 (0.55) | CA1CA2CA12CA9GABRA1 | |
| SCHEMBL29414063 | 0.77 | GABRA1 (0.55) | CA1CA2CA12CA9GABRA1 | |
| SCHEMBL23040289 | 0.76 | ROCK2 (0.33) | CA1CA2CA12CA9GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531695-B2 | Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICAL, INC (US) | 2009-05-12 | — | — | US | claimed |
| US-20070129392-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | claimed |
| US-20070078189-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS (US) | 2007-04-05 | — | — | US | claimed |
| EP-1636160-A4 | NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS (US) | 2006-09-27 | — | — | EP | claimed |
| EP-1636160-A2 | NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | Auspex Pharmaceuticals (US) | 2006-03-22 | — | — | EP | claimed |
| WO-2005000233-A2 | NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS (US) | 2005-01-06 | — | — | WO | claimed |
| EP-2583958-B1 | Ligands for metals and improved metal-catalyzed processes based thereon | MASSACHUSETTS INST TECHNOLOGY (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-2583958-A1 | Ligands for metals and improved metal-catalyzed processes based thereon | Massachusetts Institute of Technology (MIT) (US) | 2013-04-24 | — | — | EP | disclosed |
| US-7560582-B2 | Ligands for metals and improved metal-catalyzed processes based thereon | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-07-14 | — | — | US | disclosed |
| US-7531695-B2 | Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICAL, INC (US) | 2009-05-12 | — | — | US | disclosed |
| US-7468462-B2 | Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS (US) | 2008-12-23 | — | — | US | disclosed |
| US-7358398-B2 | of aromatic groups using transition metal catalysis in compressed carbon dioxide; intermediates | ASTRAZENECA UK LIMITED (GB) | 2008-04-15 | — | — | US | disclosed |
| US-20080033171-A1 | Ligands for Metals and Improved Metal-Catalyzed Processes Based Thereon | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-02-07 | — | — | US | disclosed |
| US-20040171833-A1 | Ligands for metals and improved metal-catalyzed processes based thereon | NATIONAL SCIENCE FOUNDATION | 2004-09-02 | — | — | US | disclosed |
| US-20040010149-A1 | Ligands for metals and improved metal-catalyzed processes based thereon | NATIONAL SCIENCE FOUNDATION | 2004-01-15 | — | — | US | disclosed |
| EP-1354887-A1 | Ligands for metals and improved metal-catalyzed processes based thereon | Massachusetts Insitute of Technology (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20020156295-A1 | Ligands for metals and improved metal-catalyzed processes based thereon | NATIONAL SCIENCE FOUNDATION | 2002-10-24 | — | — | US | disclosed |
| US-6307087-B1 | USE OF CATALYSTS COMPRISING THESE LIGANDS IN TRANSITION METAL-CATALYZED CARBON-HETEROATOM AND CARBON-CARBON BOND-FORMING REACTIONS. | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2001-10-23 | — | — | US | disclosed |
| EP-1097158-A2 | LIGANDS FOR METALS AND METAL-CATALYZED PROCESSES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2001-05-09 | — | — | EP | disclosed |
| WO-2000002887-A2 | LIGANDS FOR METALS AND METAL-CATALYZED PROCESSES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2000-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010149-A1 | Ligands for metals and improved metal-catalyzed processes based thereon | THEM6, SOD1, SLC30A6 | CA1 314/4885CA2 131/4885CA12 73/4885 |
| US-20080033171-A1 | Ligands for Metals and Improved Metal-Catalyzed Processes Based Thereon | THEM6, SOD1, SLC30A6 | CA1 314/4885CA2 131/4885CA12 73/4885 |
| US-20070078189-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | GPR119, IGF1R, CCNE2 | CA1 4763/4885CA2 3265/4885CA12 3832/4885 |
| US-20040171833-A1 | Ligands for metals and improved metal-catalyzed processes based thereon | THEM6, SLC30A6, SOD1 | CA1 210/4885CA2 88/4885CA12 52/4885 |
| US-20020156295-A1 | Ligands for metals and improved metal-catalyzed processes based thereon | THEM6, SOD1, SLC30A6 | CA1 314/4885CA2 131/4885CA12 73/4885 |
| US-20070129392-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | IGF1R, INSR, BRCA1 | CA1 4786/4885CA2 3916/4885CA12 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.